GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Aurobindo Pharma, Cipla, and Viatris to supply long-acting injectable cabotegravir for HIV treatment in 133 countries.

UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, ...